Login / Signup

Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.

Maythinee ChantadisaiH R KulkarniR P Baum
Published in: European journal of nuclear medicine and molecular imaging (2020)
Even rarely occurred, the OS is gravely compromised in t-MN patients after PRRT, and even less in the AML subgroup (6 months). Higher platelet value was a significant prognostic parameter for longer OS in t-MN patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • acute myeloid leukemia
  • randomized controlled trial
  • patient reported outcomes
  • study protocol